Investors
-
March 28, 2023Umecrine Cognition secures additional funding to progress its drug development projectsSTOCKHOLM – March 28, 2023. Umecrine Cognition today announces that the company has secured additional funding of SEK 31,6 million to progress the...
-
January 17, 2023Umecrine Cognition announces Orphan Drug Designation granted by FDA for golexanoloneSTOCKHOLM – January 17, 2023. Umecrine Cognition AB today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
-
January 9, 2023Umecrine Cognition will attend the JP Morgan 41st Annual Healthcare Conference 2023 in San FranciscoSTOCKHOLM – January 9, 2023. Umecrine Cognition today announces that the company will attend the JP Morgan 41st Annual Healthcare Conference in San...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.